• Keine Ergebnisse gefunden

Correction to: Molecular remission using three monoclonal antibodies followed by allogeneic bone marrow transplantation in an infant with refractory ALL

N/A
N/A
Protected

Academic year: 2022

Aktie "Correction to: Molecular remission using three monoclonal antibodies followed by allogeneic bone marrow transplantation in an infant with refractory ALL"

Copied!
1
0
0

Wird geladen.... (Jetzt Volltext ansehen)

Volltext

(1)

Vol.:(0123456789)

1 3

https://doi.org/10.1007/s00277-021-04581-1 CORRECTION

Correction to: Molecular remission using three monoclonal antibodies followed by allogeneic bone marrow transplantation in an infant with refractory ALL

Bernd Gruhn1  · Grit Brodt1 · Susan Wittig1 · Thomas Ernst2 · Jana Ernst1

© Springer-Verlag GmbH Germany, part of Springer Nature 2021

Correction to: Annals of Hematology

https://doi.org/10.1007/s00277-020-03957-z The article “Molecular remission using three monoclonal antibodies followed by allogeneic bone marrow transplan- tation in an infant with refractory ALL”, written by Bernd Gruhn, Grit Brodt, Susan Wittig, Thomas Ernst and Jana Ernst, was originally published Online First without Open Access. After publication in volume 99, issue 5, page 1133–1134 the author decided to opt for Open Choice and to make the article an Open Access publication. Therefore, the copyright of the article has been changed to © The Author(s) 2021 and the article is forthwith distributed under the terms of the Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribu- tion and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third

party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permit- ted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://

creat iveco mmons. org/ licen ses/ by/4.0.

The original article has been corrected.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at https://

doi. org/ 10. 1007/ s00277- 020- 03957-z

* Bernd Gruhn

bernd.gruhn@med.uni-jena.de

1 Department of Pediatrics, Jena University Hospital, Jena, Germany

2 Department of Internal Medicine II, Jena University Hospital, Jena, Germany

Annals of Hematology (2021) 100:2423

Referenzen

ÄHNLICHE DOKUMENTE

This article summarizes clinical trials on immunotherapy of pancreatic cancer using the murine monoclonal antibodies (MAbs) 17-1A and BW 494. In addition, the use of MAb

Based on these considerations, the aim of the present study was defined as an evaluation of different types of filling systems (piston pump, radial peristaltic pump and linear

My thesis proposes to harness the endochondral ossification paradigm for either bone regeneration purposes by using in vitro generated devitalized hypertrophic cartilage

Applying a widely used mAb against CD34 to undecalcified human iliac crest sections from a 53-year-old healthy male patient revealed that CD34 was present in endothelia of small

B) Put the words in the correct order to make questions. Then answer the questions. C) Match the comments on the left with the responses on the right. Bridget lives in the flat.

If the object of the first verb is also the object of the second verb, we can leave out the relative pronoun. Make one sentence from the

_______Hector comes from a country in South America that I visited

First, the antibody pool of αB2b-138, αB2b-49 and αB2b-138hom do not contain any heavy chain fragments and consequently no inactive components and second in the FcγRIIIA binding